Journal article
Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families
H Thorne, AJ Willems, E Niedermayr, IMY Hoh, J Li, D Clouston, G Mitchell, S Fox, JL Hopper, D Bolton
Cancer Prevention Research | Published : 2011
Abstract
The role of a germ-line BRCA2 mutation in the development of prostate cancer is established, but the clinical presentation linked to outcome for this group of men has not been well described. A total of 148 men from 1,423 families were ascertained from the kConFab consortium. Each participant met the following criteria: (i) a verified case of prostate cancer; (ii) confirmed as either a carrier or noncarrier of a family-specific BRCA pathogenicmutation; (iii) comprehensive clinical and treatment data were available. Clinical data were linked to treatment received and overall survival was analyzed by Kaplan-Meier. Prostate cancer in men from breast cancer-prone families has a high risk of dise..
View full abstractGrants
Awarded by Cancer Australia
Funding Acknowledgements
We thank Professor Joe Sambrook for his continual help, advice, and guidance throughout the development of this project and preparation of the manuscript. We also wish to thank all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded 2001-2009 by NHMRC and currently by the National Breast Cancer Foundation and Cancer Australia #628333) for their contributions to this resource, and the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia